Cart
sales@molnova.com
Deracoxib
CAS No. 169590-41-4
Deracoxib( SC-046 | SC-46 | SC-59046 )
Catalog No. M12584 CAS No. 169590-41-4
A selective COX-2 inhibitor that is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 50MG | 28 | In Stock |
|
| 100MG | 41 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 108 | In Stock |
|
| 1G | 152 | In Stock |
|
Biological Information
-
Product NameDeracoxib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA selective COX-2 inhibitor that is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).
-
DescriptionA selective COX-2 inhibitor that is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).
-
In Vitro——
-
In Vivo——
-
SynonymsSC-046 | SC-46 | SC-59046
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX-2
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number169590-41-4
-
Formula Weight397.3716
-
Molecular FormulaC17H14F3N3O3S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=S(C1=CC=C(N2N=C(C(F)F)C=C2C3=CC=C(OC)C(F)=C3)C=C1)(N)=O
-
Chemical NameBenzenesulfonamide, 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Spyra S, et al. Br J Pharmacol. 2017 Aug;174(16):2696-2705.
2. McMillan SK, et al. J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9.
molnova catalog
related products
-
Ebselen
Ebselen is a mimic of glutathione peroxidase and can also react with peroxynitrite.
-
6-paradol
6-paradol is a pungent phenolic substance found in ginger and other Zingiberaceae plants and exhibits a variety of biological activities including anti-cancer anti-inflammatory and anti-oxidative activitiesneuroprotective Effects.
-
Orientin
Orientin may be regarded as a candidate therapeutic agent for treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.
